Transcatheter (percutaneous) Mitral Valve Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Transfemoral implantation, Transapical implantation), By Distribution Channel (Hospitals, Cardiac care centers, Others), and Region Forecast 2019-2030

Transcatheter Percutaneous Mitral Valve Market size was valued at US$ 5.7 billion in 2023 and is poised to grow at CAGR 6.4% from 2024-2030. report gives a comprehensive outlook on butyric acid derivatives across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on gives historical, current, and future market sizes (US$ Mn) on the basis of product, animal feed and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Key stakeholders of the global butyric acid derivatives market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged. Transcatheter (percutaneous) mitral valve is used to treat mitral regurgitation (MR). Mitral valve disease is the second most common valvular heart disease in adults. MR is classified as either primary (degenerative) or secondary (functional). Primary MR from degenerative valve disease is due to a primary disruption of the mitral valve apparatus from either prolapsed or flail leaflets. Secondary MR on the other hand is due to remodeling of the left ventricle resulting inappropriate coaptation of the mitral leaflets. Trans catheter heart valve implantation procedure helps in replacing the heart valve with prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. This increases survival rate of patients and helps in reducing severe degenerative aortic stenosis.